Highlights: -CX 2014 audience recognises the impact of drug-eluting balloons -No type I or III endoleaks with the Incraft system for EVAR at two years -Lindsay Machan: Radiation hazards -Mark S Whiteley: Heat ablation -Profile: Cliff Shearman
Highlights: -CX 2014 audience recognises the impact of drug-eluting balloons -No type I or III endoleaks with the Incraft system for EVAR at two years -Lindsay Machan: Radiation hazards -Mark S Whiteley: Heat ablation -Profile: Cliff Shearman